Vaccine Research最新文献

筛选
英文 中文
Green Synthesized Silver Nanoparticles Using Anise (Pimpinella anisum L.) have Antibacterial Effects 利用茴香(Pimpinella anisum L.)合成绿色银纳米粒子具有抗菌作用
Vaccine Research Pub Date : 2020-06-01 DOI: 10.29252/vacres.7.1.17
Nassir Rashnaei, S. Siadat, A. Sepahi, M. Mirzaee, G. Bahramali, A. Joshaghani
{"title":"Green Synthesized Silver Nanoparticles Using Anise (Pimpinella anisum L.) have Antibacterial Effects","authors":"Nassir Rashnaei, S. Siadat, A. Sepahi, M. Mirzaee, G. Bahramali, A. Joshaghani","doi":"10.29252/vacres.7.1.17","DOIUrl":"https://doi.org/10.29252/vacres.7.1.17","url":null,"abstract":"Introduction: Silver nanoparticles are particles of silver with a size of 1 to 100 nm. These agents have various applications and particularly have received much attention for their antibacterial activity and their use in vaccine production. Among the various methods of synthesizing nanoparticles, using plants due to their high reducing capabilities and also their eco-friendliness is of interest. Methods: Silver nanoparticles (AgNPs) were synthesized using plant anise (Pimpinella anisum L.) and validated using UVspectrophotometer, transmission electron microscopy and Fourier transform infrared spectroscopy. The produced AgNPs were used against Escherichia coli, Salmonella typhimurium, Staphylococcus aureus and Enterococcus faecalis to examine their antibacterial activities via agar well diffusion, disk diffusion and minimum inhibitory concentration methods. Furthermore, AgNPs were used in combination with three antibiotic disks, namely, Ceftriaxone, Tetracycline and Gentamicin to seek any cooperative effect. Results: Antibacterial effects due to the synthesized AgNPs were observed toward E. coli, S. aureus, S. typhimurium in this order; however, E. faecalis showed the highest resistance to the synthesized AgNPs. Conclusion: AgNPs synthesized using anise had similar antibacterial effects as conventional antibiotics; however with potentially less side effects. Citation: Rashnaei N, Siadat S D, Akhavan Sepahi A, Mirzaee M, Bahramali G, Arab Joshaghani A. Green Synthesized Silver Nanoparticles Using Anise (Pimpinella anisum L.) have Antibacterial Effects. vacres. 2020; 7 (1) :17-24. DOI: 10.29252/vacres.7.1.17","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48508592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
A Community Based Cohort Study on Usefulness of Leishmanin Skin Test in Detection of Immunoreactivity Against Leishmania donovani Infection in an Endemic Area of Kala-Azar, Bihar, India 印度比哈尔邦卡拉阿扎尔流行区利什曼原虫皮试用于检测对杜氏利什曼病感染的免疫反应性的社区队列研究
Vaccine Research Pub Date : 2019-12-01 DOI: 10.29252/vacres.6.2.42
N. Verma, S. Bimal, Kumar Gupta Anil, C. Lal, A. Ranjan, R. B. Verma, K. Pandey, V. Rabidas, S. Kar, P. Das, Icmr-Rmrims, Aiims patna
{"title":"A Community Based Cohort Study on Usefulness of Leishmanin Skin Test in Detection of Immunoreactivity Against Leishmania donovani Infection in an Endemic Area of Kala-Azar, Bihar, India","authors":"N. Verma, S. Bimal, Kumar Gupta Anil, C. Lal, A. Ranjan, R. B. Verma, K. Pandey, V. Rabidas, S. Kar, P. Das, Icmr-Rmrims, Aiims patna","doi":"10.29252/vacres.6.2.42","DOIUrl":"https://doi.org/10.29252/vacres.6.2.42","url":null,"abstract":"Introduction: Control efforts of visceral leishmaniasis (VL) are hindered due to inappropriate early case detection of Leishmania infection with varying degree of susceptibility to develop the disease. Methods: We assessed the current infection status using Leishmanin skin test (LST) and direct agglutination test (DAT) in a cohort population (206 randomly selected individuals) in a VL endemic area of Bihar, India. Results: Cellular immunity was revealed in 18.4% and antibody response in 18.9% of the population. The age-group of 20-29 years were most vulnerable. DAT titer was inversely proportional to duration of past history of VL. The houses having present or past history of kala-azar in family were observed with high Leishmanin and DAT positivity, indicating relevance of household contacts in the disease transmission. Conclusion: The reactivity of both LST and DAT tests may help in identifying the possible groups with varying degree of susceptibility and risk of infection or having prior exposure to the leishmania infection with or without development of the disease. Citation: Verma N, Bimal S, Gupta Anil K, Lal C, Ranjan A, Verma R, et al . A Community Based Cohort Study on Usefulness of Leishmanin Skin Test in Detection of Immunoreactivity Against Leishmania donovani Infection in an Endemic Area of Kala-Azar, Bihar, India. vacres. 2019; 6 (2) :42-46. DOI: 10.29252/vacres.6.2.42","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44082308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunobiological Correlates of SIV Vaccine Vectors and Macaque Tropism SIV疫苗载体与猕猴嗜性的免疫生物学相关性
Vaccine Research Pub Date : 2019-12-01 DOI: 10.29252/vacres.6.2.23
Joseph M. Antony
{"title":"Immunobiological Correlates of SIV Vaccine Vectors and Macaque Tropism","authors":"Joseph M. Antony","doi":"10.29252/vacres.6.2.23","DOIUrl":"https://doi.org/10.29252/vacres.6.2.23","url":null,"abstract":"The field of HIV vaccines received a “boost” with around 30% protection obtained in the RV144 randomized, double-blind, efficacy trial in Thailand. Currently, 560 clinical trials in HIV vaccine development are registered as complete and results are expected from several of these studies. The modest success attained at this time may be attributed to early attempts at identifying an animal model to test vaccine efficacy. Macaque models of HIV-1 infection have revealed viral infection, transmission, pathogenesis, and prevention. Identification of simian immunodeficiency virus (SIV) and its related strains served as the macaque counterpart of HIV and through genetic engineering, enabled chimera development that explored how macaques respond to a human antigen as well. Along with understanding viral infection, it is worth exploring the genetic repertoire of macaques for determining how the major histocompatibility complex and anti-retroviral restriction factors offer barriers to viral replication.","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46456957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prospective on Different Approaches for Vaccine Development Against COVID-19: Past Lessons and Future Challenges 展望针对COVID-19疫苗开发的不同方法:过去的经验教训和未来的挑战
Vaccine Research Pub Date : 2019-12-01 DOI: 10.29252/vacres.6.2.14
Pooneh Rhimi, M. Aghasadeghi
{"title":"Prospective on Different Approaches for Vaccine Development Against COVID-19: Past Lessons and Future Challenges","authors":"Pooneh Rhimi, M. Aghasadeghi","doi":"10.29252/vacres.6.2.14","DOIUrl":"https://doi.org/10.29252/vacres.6.2.14","url":null,"abstract":"a against","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43882488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Could trivalent LAIV protect against both genetic lineages of influenza B virus? 三价LAIV是否可以预防乙型流感病毒的两种遗传谱系?
Vaccine Research Pub Date : 2019-06-10 DOI: 10.29252/vacres.6.1.13
I. Kiseleva, Stepanova Ev, E. Krutikova, Donina Sa, Rekstin Ar, E. Bazhenova, Maria Pisareva, A. Katelnikova, K. Kryshen, A. Muzhikyan, E. Grigorieva, L. Rudenko
{"title":"Could trivalent LAIV protect against both genetic lineages of influenza B virus?","authors":"I. Kiseleva, Stepanova Ev, E. Krutikova, Donina Sa, Rekstin Ar, E. Bazhenova, Maria Pisareva, A. Katelnikova, K. Kryshen, A. Muzhikyan, E. Grigorieva, L. Rudenko","doi":"10.29252/vacres.6.1.13","DOIUrl":"https://doi.org/10.29252/vacres.6.1.13","url":null,"abstract":"Introduction: The global co-circulation of two influenza B virus genetic lineages known as B/Yamagata and B/Victoria may lead to a mismatch between the circulating virus and the strain recommended for use in influenza vaccines. Little is known about the protective efficacy of unmatched influenza B strains, especially when it comes to live attenuated influenza vaccine. The main purpose of this study was to demonstrate the viability of using live attenuated influenza vaccine developed on B/USSR/60/69 backbone to protect against heterologous influenza B challenge infection. Methods: To estimate the potential crossprotective activity of monoand trivalent live attenuated vaccines based on B/Victoria or B/Yamagata genetic lineage virus against a heterological challenge, ferrets were given one dose of vaccine and then were challenged with influenza B virus. The ferrets were then monitored for clinical signs associated with influenza infection. Samples of the ferrets’ airways were tested for the presence of the challenge virus. Results: Monoand trivalent live attenuated influenza vaccines were shown to be safe and cross-protective against genetically different influenza B viruses based on virological and histological data and clinical signs. A lower titer of heterologous challenge virus in the airways of the vaccinated ferrets compared to mock-vaccinated animals inoculated with the challenge virus was detected. Interestingly, B/Victoria-based vaccines were more cross-protective compared with B/Yamagata-based vaccines. Conclusion: In the case of mismatches of B component of the trivalent live attenuated influenza vaccine and lineage of the circulating influenza B viruses, one of the options could be using trivalent preparation containing a B/Victoria lineage component.","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42597619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of outer membrane vesicles of three different isolates from Pseudomonas aeruginosa 三株铜绿假单胞菌外膜囊泡的比较
Vaccine Research Pub Date : 2019-06-10 DOI: 10.29252/vacres.6.1.25
Fereshteh Satarian, T. Nejadsattari, F. Vaziri, S. Siadat
{"title":"Comparison of outer membrane vesicles of three different isolates from Pseudomonas aeruginosa","authors":"Fereshteh Satarian, T. Nejadsattari, F. Vaziri, S. Siadat","doi":"10.29252/vacres.6.1.25","DOIUrl":"https://doi.org/10.29252/vacres.6.1.25","url":null,"abstract":"Introduction: Pseudomonas aeruginosa (PA) is an opportunistic mucosal human pathogen responsible for a wide range of acute and chronic infections. PA releases outer membrane vesicles (OMVs) in all situations and environments. OMVs are bilayered proteolipids ranging in diameter from 50 to 250 nm. Recent studies have demonstrated that OMVs are related to PA pathogenesis. According to strain-dependent components of OMV, in this study, we aimed at identifying significant physicochemical differences among OMVs from lab strain ATCC 17933, an antibiotic-susceptible and an antibiotic-resistant PA clinical strains. Methods: OMVs of the three strains were purified using differential centrifugation with deoxycholate and EDTA. Chemical analyses were assessed using nano-drop, SDSPAGE and the limulus amebocyte lysate (LAL) test. Moreover, electron microscopy was performed to verify the stability and totality of the extracted OMVs. Results: The nanodrop method and the LAL test showed that total protein and endotoxin concentrations were significantly different among all the 3 mentioned strains. In addition, the quality control of OMVs illustrated that the lab and the antibiotic-susceptible strains were approximately similar in terms of the vesicle yield and size; however they differed in protein contents. Moreover, OMVs generated from the resistant strain had a higher density, smaller size and sharper protein bands as observed by electron microscopy and SDSPAGE, respectively. Endotoxins measurement were 2.8, 2.9 and 3 EU/ml for OMVs from the lab, the antibiotic-susceptible and the resistant strains, respectively. Conclusion: The results of the current study demonstrated that OMVs of the resistant PA strain may produce vesicles with a particular composition. This characterization profile provides a basis for future studies to elucidate immune responses to OMVs from PA and developing vaccines against Pseudomonal infections as a common nosocomial infection with extremely high resistance to antibiotics.","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46873029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Seroepidemiology of pertussis in a set of under one year old Iranian children 一组一岁以下伊朗儿童百日咳的血清流行病学
Vaccine Research Pub Date : 2019-06-10 DOI: 10.29252/vacres.6.1.1
Ali Badamchi, S. Siadat, F. Shahcheraghi
{"title":"Seroepidemiology of pertussis in a set of under one year old Iranian children","authors":"Ali Badamchi, S. Siadat, F. Shahcheraghi","doi":"10.29252/vacres.6.1.1","DOIUrl":"https://doi.org/10.29252/vacres.6.1.1","url":null,"abstract":"Introduction: Pertussis or whooping cough is one of the vaccine preventable diseases. The purpose of this study was to evaluate the seroepidemiology of pertussis in two groups of children (i.e. under 2 months and 2-12 months old) who had been admitted to Tehran Children Hospital. Methods: Sampling from the children was done along with completing a questionnaire including demographic information, clinical symptoms and the history of the parents coughing. The levels of IgG-Ptx antibody were then measured using the children's sera. Results: Overall, 10.8% of the children were not immune, 78.3% were immune, and 10.9% had recent pertussis infections. Moreover, 19.4% of the female and 13.1% of the male subjects had the infection. In the age group less than two months, 16.6% were infected. The likelihood of new infection among the children less than 2 months old was 1.2 times higher than the control group (P < 0.004). Fifty percent of the children who were diagnosed with cyanosis in their clinical examinations had a recent infection (P <0.001). Conclusion: Pertussis appears to be endemic in Iran with children under one year old being at high risk of the infection. In this regard, maternal vaccination against pertussis for conferring passive immunity to the newborns could be considered as a protection","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45520640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The current status of bacillus Calmette‐Guérin vaccine protective efficacy 卡介苗-谷氨酰胺疫苗保护效果的现状
Vaccine Research Pub Date : 2019-06-10 DOI: 10.29252/vacres.6.1.29
P. Méndez-Samperio
{"title":"The current status of bacillus Calmette‐Guérin vaccine protective efficacy","authors":"P. Méndez-Samperio","doi":"10.29252/vacres.6.1.29","DOIUrl":"https://doi.org/10.29252/vacres.6.1.29","url":null,"abstract":"Bacillus Calmette‐Guérin (BCG) vaccine against pulmonary tuberculosis (TB) exhibits poor protective efficacy. However, BCG is the only licensed vaccine against human TB. This review discusses the main research progress in the field of TB vaccine development and will summarize the current status as well as the main challenges for the development of a safer and more efficient TB vaccine.","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41455126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pasteur Institute of Iran; a Leading Institute in the Production and Development of Vaccines in Iran 伊朗巴斯德研究所;伊朗领先的疫苗生产和开发研究所
Vaccine Research Pub Date : 2019-06-10 DOI: 10.29252/vacres.6.1.33
Sholeh Maslehat, D. Doroud, E. Mostafavi
{"title":"Pasteur Institute of Iran; a Leading Institute in the Production and Development of Vaccines in Iran","authors":"Sholeh Maslehat, D. Doroud, E. Mostafavi","doi":"10.29252/vacres.6.1.33","DOIUrl":"https://doi.org/10.29252/vacres.6.1.33","url":null,"abstract":"The 100-year-old Pasteur Institute of Iran is a research, manufacturing, and educational institute providing services in terms of public health. It has taken great steps towards producing required vaccines in Iran. The institute has played a key role in controlling infectious diseases in Iran by producing many vaccines such as smallpox, cholera, Bacillus Calmette–Guérin (BCG) and recombinant hepatitis B as well as introducing infectious disease control programs and making use of diagnostic laboratories. The institute is currently pursuing a program to develop its production lines for human polysaccharide-conjugate vaccines and viral vaccines for the health system of Iran. This paper reviews manufacturing activities of this institute over the past 100 years. INTRODUCTION Vaccines prevent deaths of millions of children in the world. Growing efforts are being made to produce new vaccines and prevent other diseases. Given the usefulness of the vaccines, it has been argued that the life expectancy has been increased up to 30 years on average in the twentieth century (1). Vaccines consist of substances that are introduced into the body and provide immunization, and thus microbes cannot cause diseases in the body for a specified period. Vaccines are often used to prevent illnesses, and sometimes to treat and protect against microbes entering into the body. Sera are also injectable components containing a microbial substance derived from the inoculation of a microbial pathogen to animals; they are often used to treat diseases and sometimes to protect body against diseases (2). Before the Constitutional Revolution (1906 AD), the Iranian government was not taking the responsibility for the national health. After this period, the National Consultative Assembly passed laws to improve the national health and involved the government in this field. The Pasteur Institute of Iran was established to promote the public health of Iranians during the late Qajar period. During the first Pahlavi period, the provision of health was practically state-owned. In the second Pahlavi period and at the onset of the World War II, famine and infectious diseases became widespread in Iran and the role of prevention programs became more important in controlling infectious diseases (3). In 1953, the general vaccination law was passed by the National Consultative Assembly, followed by the immunization of target groups. Seemingly, this new preventive approach, along with Iranians gradual independence on domestic production of vaccines, was a symbol of the emergence of a dominant medical model in Iran and reduced dependence on foreign products. In the past 100 years, the productions of high-quality vaccines in accordance with the national and international standards and regulations against vaccine-preventable diseases in the Pasteur Institute of Iran and Razi Vaccine and Serum Research Institute have been successful activities to protect target groups, provide immunization and reduce t","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44185239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Modification of SPION nanocarriers for siRNA delivery: A therapeutic strategy against HIV infection 用于siRNA递送的SPION纳米载体的修饰:一种对抗HIV感染的治疗策略
Vaccine Research Pub Date : 2019-06-01 DOI: 10.29252/vacres.6.1.43
Vahid Iranpur Mobarakeh, M. Modarressi, P. Rahimi, A. Bolhassani, E. Arefian
{"title":"Modification of SPION nanocarriers for siRNA delivery: A therapeutic strategy against HIV infection","authors":"Vahid Iranpur Mobarakeh, M. Modarressi, P. Rahimi, A. Bolhassani, E. Arefian","doi":"10.29252/vacres.6.1.43","DOIUrl":"https://doi.org/10.29252/vacres.6.1.43","url":null,"abstract":"and the effectiveness of the modified SPION in siRNA delivery to HEK293 cells was evaluated. Results: The optimal concentration (50 µg/mL) of the modified SPION-containing anti-tat siRNA (with a range size of 50-70 nm and average zeta potential of +25 mV) was significantly internalized into the cells and decreased the expression of HIV-1 tat, more than 80%. Moreover, the nanoparticles showed no considerable toxicity on the cells. Conclusion: SPION could be optimized as a probable RNA/vaccine delivery system into target cells. Therefore, this study offers a therapeutic strategy against HIV or other infectious diseases.","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41595850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信